Jeanmarie Guneot: Research Scientist and CEO of Amphivena Therpeutics

Dr. Jeanmarie Guenot has more than two decades of experience in the pharmaceutical and biotech industries, both as an executive and a researcher. She specializes in turnarounds and building up startups, and is currently the CEO of Amphivena Therapeutics, Inc., which develops bi-functional antibody therapeutics for cancers of the blood and lymph system.

Read more: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

Dr. Jeanmarie Guenot earned her PhD at UC San Francisco, where she studied medicinal chemistry. She later became a Principal Investigator in R&D at Hoffman-LaRoche, developing new anticancer drugs and drugs for autoimmune and metabolic diseases. After a distinguished career in research, she moved on to business school at Wharton before beginning her career as an executive at Atlas Ventures, where she helped to develop biotech companies.

Dr. Jeanmarie Guenot was also the founder of SKS Ocular, an incubator for opthalmic start-ups, one of the first incubators of its kind. She later returned to Hoffman-LaRoche as an executive and went on to join PDL Biopharma, where she was in charge of licensing and M&A and put together several multi-million dollar deals on takeda.com. In addition to heading up Amphivena Therapeutics, she runs a consulting and venture capital firm called Guenot LLC, where she uses her experience in the pharmaceutical industry to help start-ups prosper and negotiate new deals.

Learn more about Jeanmarie Guenot: http://amphivena.com/amphivena_leaders/jeanmarie-guenot-ph-d/